If you’ve ever wondered whether cosmetics are really drugs, then you’ve probably wondered why they are not considered to be. But there’s good news: Japan’s Pharmaceutical and Medical Device Agency oversees the regulation of cosmetic products. The agency, in conjunction with the Ministry of Health, Labour, and Welfare, is responsible for assessing the safety of both drugs and cosmetics. The Japanese Pharmaceutical Affairs Law was replaced by the Pharmaceutical and Medical Device Act in November 2014. In that new Act, cosmetics and quasi drugs are defined in separate categories. Cosmetics fall into the first category, while quasi drugs fall into the second.
Qualities of quasi-drugs
Japanese authorities have established a rigorous regulatory framework for the manufacturing of cosmetics. This includes more stringent standards for product safety and quality assurance than in the U.S., and importers are responsible for ensuring compliance with these requirements. Cosmetics must also meet specific requirements for drug marketing authorization, which requires the importer to obtain a special license and appoint a designated drug marketing authorization holder. As with pharmaceuticals, information on the packaging must be provided in Japanese.
In Japan, a variety of quasi-drugs have been approved by the Ministry of Health, Labor and Welfare (MHLW). These products inhibit the activity of tyrosinase and accelerate degeneration. Several products in this category have been developed in Japan, which have undergone extensive testing and clinical trials. This review classifies these products and discusses the opportunities and challenges facing the industry in the future.
Regulations for quasi-drugs
While regulations for the classification of cosmetics as quasi-drugs are similar to those for drugs, the requirements for the importation of cosmetics are more stringent. Importers of cosmetics must be appointed as drug marketing authorization holders, obtain specific licenses, and ensure compliance with all required standards. For quasi-drugs, the regulatory revision process consists of reviewing the formula and label, toxicity evaluation of ingredients, and indication of warnings and precautions for use.
The classification of cosmetics as quasi-drugs differs from that for medicines. As a non-pharmaceutical, cosmetics are products with the same ingredients as medicines but have a much weaker effect on the human body. Examples of cosmetics are nutritional drinks, shampoos, hair-growth products, and facial products. Non-EU cosmetics also require registration of ingredients and submit notifications before they are permitted to enter the Japanese market.
Restrictions on the volume of product sold
The process by which a cosmetic becomes a quasi drug is different than that for a pharmaceutical. In 1960, the Pharmaceutical Affairs Law (PA) united the regulatory systems of both the pharmaceutical and the cosmetic industries. The law also mandated the use of all ingredients and the development of new cosmetic standards. As health awareness has grown, consumers are increasingly interested in these products. And international distribution is advancing.
To manufacture a cosmetic, it must meet the specifications set by the Pharmaceutical Affairs Law. It must state the manufacturing code, weight, and serial number of the manufacturer. It must also list the main contents. This information must be gathered from several sources to ensure that a cosmetic is free from harmful components. Manufacturers must also obtain a Marketing License. If their product contains any of these ingredients, they must declare it on the label.
Mechanisms of action of quasi-drugs
The classification of cosmetics as quasi-drugs has become more difficult in recent years, but it is possible to define their components on the basis of their physicochemical properties. This workflow involves considering component characteristics and ingredient categories according to OECD TG439, and using human skin tests to evaluate ingredients that cause weak skin irritation. The process is outlined below. There is also a potential for drug repositioning, which is a process that identifies biologically active ingredients with known safety profiles.
Regulatory approvals are required for the marketing of cosmetics, as well as their safety. This process can take up to two years, depending on the active ingredient. If the ingredient contains a drug-like substance, regulatory approval may be required. Cosmetics and their pre-approval dossiers are reviewed by BIORIUS and can also be submitted to the PMDA. The FDA has the final authority to approve or disapprove a product, so it is important to follow the regulations.
Market scenario for quasi-drugs
This market report offers a comprehensive analysis of the current and upcoming market scenario for cosmetics as quasi-drugs. It includes a top-to-bottom evaluation of the industry, including the key drivers, challenges, and opportunities for the industry. The report includes data on product launches, clinical trial pipelines, adherence rates, patents, and application dominance, as well as an analysis of the market’s dynamics.
In addition, the report will describe the competitive aspect of the market and include regulatory approvals in Japan and other countries in the Asia Pacific region. The report will also describe the current regulatory framework, the process of acquiring these approvals, and the approval process. Cosmetics are often categorized into several different categories, depending on their intended use. Regulatory approvals are required for products in several categories, including drugs for specific gastrointestinal disorders.